ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ruxolitinib

Also written as “Ruxolitinib”, “Ruxolitinib cream” and “Ruxolitinib Cream”.

Its studies are mostly in Primary Myelofibrosis · Dermatitis, Atopic · Vitiligo · Graft vs Host Disease · Pancreatic Neoplasms, led by 3 companies.

Drug pageRuxolitinib: every studyAll 302 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 13, 202390 company-led studies, 14 open or runningNext primary completion: Dec 9, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyteits history only689 open or runningphase 4since Jan 13, 2023Jul 30, 2007Dec 9, 2026phase 1 · NCT07049575
Novartis214 open or runningphase 4since Mar 16, 2012Jul 6, 2009May 10, 2029phase 4 · NCT06824103
Suzhou Junjing BioSciencesits history only11 open or runningphase 2since Mar 27, 2025Mar 27, 2025Oct 31, 2027phase 2 · NCT06909136

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Jul 6, 2009.

  1. Mar 6, 2014Phase 2 study in Primary MyelofibrosisNCT02091752 · 3 enrolled · Germany, Italy, Spain
  2. Mar 12, 2014Phase 3 study in Primary MyelofibrosisNCT02087059 · 51 enrolled · Japan
  3. Sep 17, 2014Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT02253277 · 5 enrolled · Germany
  4. Nov 5, 2014Phase 3 study in Polycythemia VeraNCT02292446 · 161 enrolled · Austria, Belgium, Bulgaria and more
  5. Mar 6, 2015Phase 4 study in Primary MyelofibrosisNCT02386800 · 279 enrolled · Australia, Belgium, Bulgaria and more
  6. Oct 27, 2015Phase 3 study in Primary MyelofibrosisNCT02598297 · 49 enrolled · Australia, Austria, Belgium and more
  7. Sep 18, 2016Phase 3 study in Graft vs Host DiseaseNCT02913261 · 310 enrolled · Australia, Austria, Bulgaria and more
  8. Oct 18, 2016Phase 2 study in Primary MyelofibrosisNCT02966353 · 51 enrolled · Austria, Belgium, Bulgaria and more
  9. Mar 20, 2018Phase 2 study in Graft vs Host DiseaseNCT03491215 · 45 enrolled · Belgium, Canada, Denmark and more
  10. Dec 11, 2018Phase 2 study in Graft vs Host DiseaseNCT03774082 · 46 enrolled · Brazil, Canada, Czechia and more
  11. Apr 22, 2020Phase 3 study in Cytokine Release SyndromeNCT04362137 · 432 enrolled · United States, Argentina, Brazil and more
  12. Jun 5, 2024Phase 4 study in Steroid-refractory Acute Graft Versus Host DiseaseNCT06462469 · 36 enrolled · China
  13. Feb 4, 2025Phase 4 study in Graft vs Host DiseaseNCT06824103 · 50 planned · China
  14. Jan 6, 2026Phase 1 study in Primary MyelofibrosisNCT07340138 · 3 enrolled · Japan

Ahead

  1. May 10, 2029Primary completion: phase 4 study in Graft vs Host DiseaseNCT06824103
  2. Apr 5, 2032Primary completion: phase 4 study in Primary MyelofibrosisNCT02386800

TargetBeta

“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
delgocitinibruleLEO Pharmaphase 321

Studies

All 21 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07340138Primary Myelofibrosis · Japan1Active, not recruitingJul 23, 20263
NCT06824103Graft vs Host Disease · China4RecruitingMay 10, 202950
NCT06462469Steroid-refractory Acute Graft Versus Host Disease · China4Active, not recruitingSep 3, 202636
NCT04362137Cytokine Release Syndrome · United States, Argentina, Brazil and more3CompletedOct 17, 2020432
NCT03774082Graft vs Host Disease · Brazil, Canada, Czechia and more2CompletedFeb 25, 202246
NCT03491215Graft vs Host Disease · Belgium, Canada, Denmark and more2CompletedMar 11, 202145
NCT02966353Primary Myelofibrosis · Austria, Belgium, Bulgaria and more2CompletedJul 24, 201851
NCT02913261Graft vs Host Disease · Australia, Austria, Bulgaria and more3CompletedJun 24, 2019310
NCT02598297Primary Myelofibrosis · Australia, Austria, Belgium and more3TerminatedOct 23, 201749
NCT02386800Primary Myelofibrosis · Australia, Belgium, Bulgaria and more4Active, not recruitingApr 5, 2032279
NCT02292446Polycythemia Vera · Austria, Belgium, Bulgaria and more3CompletedDec 29, 2017161
NCT02253277Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany1CompletedMar 6, 20185
NCT02087059Primary Myelofibrosis · Japan3CompletedMar 201551
NCT02091752Primary Myelofibrosis · Germany, Italy, Spain2TerminatedFeb 20153
NCT02049450beta-Thalassemia · Greece, Italy, Lebanon and more2CompletedApr 12, 201630
NCT02038036Polycythemia Vera · Australia, Belgium, Canada and more3CompletedSep 29, 2015149
NCT01558739Primary Myelofibrosis · United Kingdom4CompletedJan 201448
NCT01493414Primary Myelofibrosis · Algeria, Argentina, Austria and more3CompletedJan 26, 20172,233
NCT01392443Primary Myelofibrosis · China, Japan, Korea, Republic of and more2CompletedOct 31, 2017120
NCT01433445Primary Myelofibrosis · France, Germany, Ireland and more1CompletedJun 22, 202061
NCT00934544Primary Myelofibrosis · Austria, Belgium, France and more3CompletedMar 4, 2015219

How it is read

Names in the registry

  • “Ruxolitinib”, 44 entries
  • “Ruxolitinib cream”, 14 entries
  • “Ruxolitinib Cream”, 11 entries
  • “ruxolitinib”, 6 entries
  • “Ruxolitinib phosphate cream”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.